Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00470275 · ClinicalTrials.gov registry record · Phase 2

Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma

A Phase 2 study of Sarcoma, sponsored by Children's Oncology Group.

Completed
Registry status
Phase 2
Development phase
10
Enrollment target
20
Study locations

NCT00470275 is a Phase 2 study of Sarcoma that has completed, run by Children's Oncology Group. The registered enrollment target is 10 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00470275, a Phase 2 study of Sarcoma, has completed, sponsored by Children's Oncology Group.

COMPLETED
Registry status
Phase 2
Development phase
10 participants
Enrollment target
20
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy, such as cytarabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well cytarabine works in treating young patients with recurrent or refractory Ewing's sarcoma.

Conditions Studied

Sarcoma

Interventions

  • DRUG cytarabine

Study Locations (20)

California

  • Southern California Permanente Medical Group - Downey
  • Children's Hospital Central California - Madera
  • Children's Hospital of Orange County - Orange
  • UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco

Florida

  • Lee Cancer Care of Lee Memorial Health System - Fort Myers
  • All Children's Hospital - St. Petersburg
  • St. Joseph's Cancer Institute at St. Joseph's Hospital - Tampa
  • Kaplan Cancer Center at St. Mary's Medical Center - West Palm Beach

Illinois

  • Children's Memorial Hospital - Chicago - Chicago
  • Simmons Cooper Cancer Institute - Springfield

Alabama

  • Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham - Birmingham

Arizona

  • Arizona Cancer Center at University of Arizona Health Sciences Center - Tucson

Arkansas

  • Arkansas Cancer Research Center at University of Arkansas for Medical Sciences - Little Rock

Connecticut

  • Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center - Farmington

District of Columbia

  • Lombardi Comprehensive Cancer Center at Georgetown University Medical Center - Washington D.C.

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2007-05
Est. Completion 2013-12
Phase Phase 2

Sponsor

Children's Oncology Group

342 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00470275

The ClinicalTrials.gov registry entry for NCT00470275 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (99% lower). The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which cytarabine is the first listed.

NCT00470275 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT00470275 about?

NCT00470275 is a clinical study titled "Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma". RATIONALE: Drugs used in chemotherapy, such as cytarabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well cytarabine works in treating young patients with recurrent or refract...

What is the current status of trial NCT00470275?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2007-05. Estimated completion is 2013-12.

What conditions does trial NCT00470275 study?

This clinical trial studies the following conditions: Sarcoma.

What interventions are being tested in trial NCT00470275?

The interventions under investigation include: cytarabine (DRUG).

Who is sponsoring clinical trial NCT00470275?

This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00470275 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sarcoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Sarcoma

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.